Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies c

Benzinga46minutes ago

Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy

Seeking Alpha19:58

Baird Maintains Neutral on Mettler-Toledo Intl, Raises Price Target to $1360

Baird analyst Catherine Schulte maintains Mettler-Toledo Intl (NYSE:MTD) with a Neutral and raises the price target from $1212 to $1360.

Benzinga19:58

Mettler-Toledo Intl Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 -9.95% Baird $1212 → $1360 Maintains Neutral 04/04/2024 -13.92% Evercore ISI Group $1200 → $130

Benzinga19:57

Regeneron Pharmaceuticals And Sanof's Dupixent (Dupilumab) SBLA Accepted For FDA Priority Review For Treatment Of Adolescents With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammat

Benzinga15:00

8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard

Seeking AlphaMay 12 23:22